SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

8 Oct 2015 07:00

RNS Number : 5861B
Victrex PLC
08 October 2015
 



 

 

 

 

 

 

8 October 2015

 

Victrex plc - Full year pre-close trading update

 

"A good finish to 2015"

 

Victrex plc, an innovative world leader in high performance polymer solutions, today announces its full year pre-close trading update for the financial year ended 30 September 2015, ahead of its preliminary results on 8 December 2015.

 

Victrex delivered a good finish to 2015, with overall performance in line with our expectations, including a robust fourth quarter (Q4). For the year as a whole, the value of our balanced portfolio helped to drive growth and fully overcome headwinds including weaker sales in Oil & Gas, the effects of US Spine market consolidation on our Invibio medical business and the significant impact from foreign currency this year.

 

On a reported basis, full year Group revenue of £263.5m was 4% ahead of the prior year (FY 2014: £252.6m), with Q4 Group revenue of £68.7m being flat on the prior year period. Foreign currency, at a profit level, was a headwind of approximately £8m for the full year, which we will fully overcome.

 

At a volume level, full year Group sales volume of 4,217 tonnes was 19% ahead of the prior year (FY 2014: 3,551 tonnes). Q4 Group sales volume of 1,119 tonnes was 6% ahead of the prior year period (Q4 2014: 1,056 tonnes). Sales volumes reflect our overall momentum in VPS remaining positive during the fourth quarter, with growth across Aerospace, Automotive, General Industrial and strong Consumer Electronics volumes offsetting Oil & Gas, as previously communicated.

 

Invibio performance was in line with our previous guidance, with full year revenue of £50.5m being 5% down compared to the prior year (FY 2014: £53.4m). This reflects the effects of consolidation in the US Spine market.

 

Outlook

Our overall growth momentum remains positive as we start our new financial year. Whilst we are mindful of the continuing weakness in Oil & Gas and the need to improve Invibio performance in 2016, our balanced portfolio keeps us well placed to continue driving growth and creating value, in line with our long term strategy.

 

Enquiries:

 

Victrex plc:

Andrew Hanson, Head of Investor Relations & Communications +44 (0) 1253 898121

Louisa Burdett, Group Finance Director +44 (0) 1253 897700

David Hummel, Chief Executive +44 (0) 1253 897700

 

Pendomer Communications:

Charles Armitstead +44 (0) 203 603 5220

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions focused on the Aerospace, Automotive, Electronics, Energy and Medical markets. Every day, millions of people rely on products or applications which contain our polymers, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 35 years' experience, we are delivering leading edge solutions to shape future performance for our customers and our markets, and to drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUGGQWUUPAGAM
Date   Source Headline
4th Jun 20208:54 amRNSAdditional Listing
3rd Jun 20202:52 pmRNSHolding(s) in Company
1st Jun 20202:33 pmRNSBlock listing Interim Review
29th May 202011:58 amRNSTotal Voting Rights
21st May 20203:14 pmRNSHolding(s) in Company
19th May 202010:31 amRNSDirector/PDMR Shareholding
18th May 202010:19 amRNSDirector Declaration
11th May 20207:00 amRNSVictrex plc Interim Results
5th May 20204:13 pmRNSDisclosure of Rights Attached to Equity Shares
5th May 20209:00 amRNSDirector Declaration
30th Apr 202011:39 amRNSTotal Voting Rights
17th Apr 202012:04 pmRNSDirector/PDMR Shareholding
7th Apr 20207:00 amRNSMarket Update
3rd Apr 20207:00 amRNSDirector Declaration
31st Mar 20209:22 amRNSTotal Voting Rights
24th Mar 20202:00 pmRNSDirectorate Change
17th Mar 20203:32 pmRNSHolding(s) in Company
17th Mar 20202:52 pmRNSDirector/PDMR Shareholding
16th Mar 202010:05 amRNSHolding(s) in Company
12th Mar 202012:47 pmRNSDirector/PDMR Shareholding
3rd Mar 20209:49 amRNSDirector/PDMR Shareholding
28th Feb 202011:56 amRNSTotal Voting Rights
20th Feb 20204:50 pmRNSDirector/PDMR Shareholding
13th Feb 20201:59 pmRNSDirector/PDMR Shareholding
6th Feb 20202:34 pmRNSDirector/PDMR Shareholding
6th Feb 20201:20 pmRNSResult of AGM
6th Feb 202010:54 amRNSDirector/PDMR Shareholding
6th Feb 20207:00 amRNSAGM and Q1 Interim Management Statement
5th Feb 20204:22 pmRNSHolding(s) in Company
4th Feb 20203:42 pmRNSHolding(s) in Company
31st Jan 202010:39 amRNSTotal Voting Rights
20th Jan 202010:04 amRNSDirector/PDMR Shareholding
17th Jan 202010:38 amRNSDirector/PDMR Shareholding
13th Jan 20204:06 pmRNSHolding(s) in Company
13th Jan 20208:46 amRNSJoint Venture
3rd Jan 202012:00 pmRNSAnnual Financial Report
31st Dec 20199:00 amRNSTotal Voting Rights
23rd Dec 20191:44 pmRNSHolding(s) in Company
17th Dec 20192:20 pmRNSDirector/PDMR Shareholding
12th Dec 201910:04 amRNSDirector/PDMR Shareholding
5th Dec 20197:00 amRNSPreliminary Results 2019
2nd Dec 20191:52 pmRNSBlock listing Interim Review
29th Nov 201911:38 amRNSTotal Voting Rights
19th Nov 201911:02 amRNSDirector/PDMR Shareholding
12th Nov 201912:00 pmRNSDirectorate Change
31st Oct 201911:36 amRNSTotal Voting Rights
28th Oct 20191:41 pmRNSHolding(s) in Company
18th Oct 20194:01 pmRNSHolding(s) in Company
18th Oct 20192:20 pmRNSDirector/PDMR Shareholding
16th Oct 201911:04 amRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.